Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Outskill Genai
    HomeNewsBusinessBiocon unit gets USFDA nod for genetic anti-bacterial drug

    Biocon unit gets USFDA nod for genetic anti-bacterial drug

    Biocon Pharma, in partnership with Carnegie, has received tentative approval from the USFDA for the ANDA for Rifaximin Tablets, 550 mg, the company said in a regulatory filing.

    PTI
    October 07, 2025 / 13:40 IST
    Rifaximin tablets are indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhoea (IBS-D) in adults.

    Biocon on Tuesday said its unit in partnership with Carnegie Pharmaceuticals LLC has received approval from the US health regulator for a genetic anti-bacterial medication.

    Biocon Pharma, a wholly-owned subsidiary of the company, in partnership with Carnegie, has received tentative approval from the US Food and Drug Administration (USFDA) for the ANDA for Rifaximin Tablets, 550 mg, the company said in a regulatory filing.

    Rifaximin tablets are indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhoea (IBS-D) in adults.

    Shares of the company were trading flat at Rs 347 apiece on the BSE.

    PTI
    first published: Oct 7, 2025 01:40 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347